SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Bookmark and Share
Genetown
Experimental Johnson & Johnson Drug Works In Resistant Tuberculosis
June 4, 2009
 · 
1 min read
Bookmark and Share
Pharm Country
Why Drug Companies Prefer Twitter Over Blogs; AstraZeneca PLC, Johnson & Johnson, Centocor, Inc., and GlaxoSmithKline Reviewed
May 21, 2009
 · 
1 min read
European Cardiologists Urge Greater Use of Stents
March 20, 2009
 · 
1 min read
Pharm Country
Slings and arrows: Online Backlash Ends Johnson & Johnson’s Motrin Ad
November 18, 2008
 · 
1 min read
Policy
Johnson & Johnson, Merck Consumer Pharmaceuticals Company Announces Urgent Voluntary Nationwide Recall Of Infants’ Mylicon Gas Relief Dye Free Drops
November 17, 2008
 · 
1 min read
BioCapital
Anemia Drugs Made By Johnson & Johnson And Amgen Linked To Stroke Study Deaths: FDA Reports
September 26, 2008
 · 
1 min read
Medical Device Makers Throwing Money Down the Tube
September 19, 2008
 · 
1 min read
Job Trends
NJ to Lose More Than 800 Pharmaceutical Jobs; Johnson & Johnson (JOBS) Shifting 260 Jobs to Centocor, Inc.; Schering-Plough Corporation (JOBS) Cutting 500 and Abbott Laboratories (JOBS) Cutting 83
July 8, 2008
 · 
1 min read
BioCapital
US FDA (JOBS) Urging Black Box Warning for Epilepsy Drugs
July 8, 2008
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
December 29, 2025
 · 
5 min read
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Load More